With the evolution of scalability of peripheral blood protein glycosylation, research has expanded for new biomarkers.
Klaus Lindpaintner
Advertisement
Klaus Lindpaintner, MD, MPH is chief scientific officer and distinguished scientist at InterVenn BioSciences.
Articles by Klaus Lindpaintner
Advertisement
Latest Updated Articles
- Using Novel Biomarkers to Facilitate AI-Driven Glycoproteomics
November 2nd 2022
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Renewing Prosaic Generics for Cancer Treatment
2
Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance
3
Leveraging an Innovative Mid-Scale Manufacturing Solution to Meet Diverse Needs
4
Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape
5